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A best evidence topic was written according to a structured protocol. The question addressed was
whether the prophylactic administration of somatostatin or somatostatin analogues in patients under-
going pancreaticoduodenectomy (Whipple’s procedure) is beneﬁcial in terms of improved surgical
outcomes, reduced morbidity or reduced mortality. A total of 118 papers were found using the reported
searches of which 5 represented the best evidence (1 meta-analysis, 1 systematic review and 3 ran-
domized control trials). The authors, date, journal, study type, population, main outcome measures and
results were tabulated. There is evidence that the perioperative administration of somatostatin or so-
matostatin analogues reduces biochemical incidence of pancreatic ﬁstula but, it is still unclear if there is a
beneﬁcial effect in the incidence of clinically signiﬁcant pancreatic ﬁstula. Further adequately powered
trials with low risk of bias are necessary. From the available data, somatostatin or somatostatin analogues
have no effect on mortality post Whipple’s. Interestingly, there are only limited data available on the
cost-beneﬁt and ﬁnancial constraints imposed by this treatment, an issue that has only been addressed
in a few studies.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A best evidence topic (BET) was structured according to the
protocol described previously.1,22. Clinical problem
In surgical rounds, a patient who has recently undergone a
pancreaticoduodenectomy for pancreatic head cancer is presented.
The patient had an uneventful post-op course but there is a
persistent discharge of an amylase-rich ﬂuid from his drain in post-
operative day 10. The patient did not receive prophylactic so-
matostatin or somatostatin analogues (S/SA). A debate between
faculty members is initiated whether the patient should have
received prophylactic S/SA and if this treatment is beneﬁcial in
patients undergoing Whipple’s. You decide to perform a literature
search yourself.; fax: þ44 (0) 207 886 7950.
charakis).
ciates Ltd. Published by Elsevier Lt3. Three-part question
In [patients undergoing Whipple’s] is [perioperative prophy-
lactic use of S/SA] beneﬁcial [improved post-operative outcomes]?
4. Search strategy
Search strategy using Medline from 1980 to July 2012 using the
PubMed interface: (pancreatic resection OR pancreatic surgery OR
pancreaticoduodenectomy OR pancreatico-jejunostomy OR
pancreatico-gastrostomy OR Whipple) AND (octreotide OR so-
matostatin OR somatostatin analogues) AND (outcome OR mor-
tality OR morbidity OR results OR ﬁstula OR collection OR
complication OR hospital stay OR length of stay OR cost OR re-
covery OR intensive care unit stay). Reference lists of key articles
were also manually searched for references. Only articles written in
English and involving human subjects were included.
5. Search outcome
One hundred and eighteen articles were retrieved using the
above search. Our search retrieved randomized controlled trials
(RCTs) and meta-analyses published on this subject in thed. All rights reserved.
Table 1
Best evidence papers in English literature.
Author, date
and country
Patient group (S/SA ¼ somatostatin/
somatostatin analogues group,
PLC ¼ placebo
Study type and level of
evidence
Outcomes Key results (S/SA vs.
placebo/no treatment)
Comments
Lai et al.6
2009
China
A systematic review of Randomized
Control Trials comparing outcomes of
available measures to prevent
pancreatic ﬁstula following
pancreaticoduodenectomy e
speciﬁcally for pharmacologic
interventions (i.e. S/SA) there were 11
RCTs meeting inclusion criteria
In total 2023 patients
Level of evidence was graded as level 1
e systematic review, level 2 e at least
one properly designed RCT, level 3 e at
least one properly designed pseudo-
RCT (alternate allocation/other
method), level 4 e case series
Systematic review
(Level 1 evidence)
Pharmacologic
interventions (S/SA)
Technical interventions
There is evidence level 1
and 2 to support that
prophylactic use of S/SA
remains controversial. It
does not result in decreased
mortality. There is need for
RCTs with standardization
in deﬁnition of outcome
measurements, treatment
regimen, surgical technique
and stratiﬁcation of risk
factors
RCTs by, Yeo et al.,3
Gouillat et al.4 included.
Study by Kollmar et al.5
not available at the
time of data extraction
Gurusamy et al.7
2012
United Kingdom
A systematic review of 19 Randomized
Control Trials of perioperative
octreotide administration in patients
undergoing pancreatic surgery
In total 2245 patients
Intention to treat principle
Seventeen out of nineteen RCT of high
risk of bias
Risk ratio (RR), mean difference (MD)
with 95%conﬁdence intervals (CI) based
on an intention to treat or available
case analysis
Meta-analysis
(Level 1 evidence)
Mortality
Drug related
complications
Post-operative
complications
Incidence of pancreatic
ﬁstula
Hospital stay (days)
Re-operation rate
RR 0.80; 95% CI 0.56e1.16
RR 2.09; 95% CI 0.83e5.24
RR 0.69; 95% CI 0.60e0.79
RR 0.63; 95% CI 0.52e0.77
MD e 1.04 days 95% CI 2.54
e0.46
RR 1.26; 95% CI 0.58e2.70
Most of the trials had a
high risk of bias
No trial reported on
quality of life
assessment
Deﬁnitions of
pancreatic ﬁstula not
uniform
Yeo et al.3
2000
USA
Three hundred and eighty three (383)
participants e post-randomization
drop out 172, sample size 211 (100
females, 111 males). S/SA ¼ 104,
PLC ¼ 107
Mean age: 64.7 years
Operation performed:
pancreaticoduodenectomy
in 211 (100%)
Pathology: 147 malignancy, 22 chronic
pancreatitis
Drug and dose: octreotide versus
placebo, 250 mg subcutaneously every
8 h for 7 days
PRCT (Level 2
evidence)
Mortality
Drug related
complications
Post-operative
complications
Incidence of pancreatic
ﬁstula
Hospital stay (days)
Re-operation rate
1 vs. 0 (nsa)
None observed
42 vs. 36 (nsa)
11 vs. 10 (ns)
13.3 vs. 11.9 (nsa)
5 vs. 1 (ns)
High risk of bias (post-
randomization drop
out, randomization
process, allocation
concealment)
Pancreatic ﬁstula
deﬁnition: drainage of
>50 ml amylase rich
ﬂuid per day (3-fold
normal serum levels
and over) through
drains on or after post-
operative day 10, or
radiologically
demonstrated
pancreatic anastomotic
disruption
One of the studies with
the lowest overall
ﬁstula reporting
Gouillat et al.4
2001
France
Seventy ﬁve (75) participants (24
females, 40 males) e 8 patients did not
complete the study. S/SA¼ 38, PLC¼ 37
Mean age 60.2
Operation performed:
pancreaticoduodenectomy in 75 (100%)
Pathology: 61 malignancy, 4 chronic
pancreatitis
Drug and dose: Somatostatin versus
placebo, continuous infusion for 7 days
of 6 mg/24 h somatostatin (days 1e6)
and 3 mg/24 h (day 7) or matching
placebo (mannitol 4 mg)
PRCT (Level 2
evidence)
Mortality
Drug related
complications
Post-operative
complications
Incidence of pancreatic
ﬁstula
Hospital stay (days)
Re-operation rate
2 vs. 1 (nsa)
3 vs. 0 (b)
8 vs. 13 (nsa)
4 vs. 10 (p ¼ 0.05)
18 vs. 26 (p ¼ 0.01)
4 vs. 1 (nsa)
Low risk of bias study
Pancreatic ﬁstula
deﬁnition: Drainage of
>100 ml/day of
amylase rich drainage
ﬂuid after day 3,
persisting after day 12
or in association with
temperature >38 C or
other symptoms
requiring surgery,
drainage or transfer to
intensive care unit
Kollmar et al.5
2008
Germany,
Switzerland
Sixty seven (67) participants (26
females, 41 males). S/SA ¼ 35, PLC ¼ 32
Mean age: 62.8 years
Operation performed:
pancreaticoduodenectomy in 67 (100%)
Pathology: 33 malignancy, 16 chronic
pancreatitis
Drug and dose: octreotide versus
placebo, 100 mg subcutaneously every
8 h for 7 days
PRCT (Level 2
evidence)
Mortality
Drug related
complications
Post-operative
complications
Incidence of pancreatic
ﬁstula
Hospital stay (days)
Re-operation rate
2 vs. 1 (nsa)
Not reported
12 vs. 9 (nsa)
3 vs. 1 (nsa)
17 vs. 16 (nsa)
5 vs. 3 (nsa)
Low risk of bias
Pancreatic ﬁstula
deﬁnition: output via a
drain (surgical or
subsequently placed) of
any measurable volume
of ﬂuid on or after day 3
with an amylase
content >3 fold the
upper normal serum
levels
a ns e not signiﬁcant.
b Possibly related to the drug.
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REVIEWliterature, therefore our selection was shortened to publications
providing either level 1 on level 2 evidence (22 articles). From
these, 5 studies providing the best evidence to answer the clinical
question were identiﬁed. Two were systematic reviews published
recently (2009 and 2012) and three were randomized controlled
trials (RCTs). These are presented in Table 1.
6. Results
Three RCTs were included in our BET article. The study by Yeo
et al.3 was the ﬁrst RCT to address the question by including
exclusively patients undergoing a pancreaticoduodenectomy. In
total 383 patients were enrolled and randomized. However there
was a considerable rate of post-randomization drop-outs in this
study (118 patients eventually did not undergo pan-
creaticoduodenectomy, 14 had a total pancreatectomy and 40 did
not receive the minimum of a 5-day course of octreotide), thus
allowing a total of 211 patients for analysis. The dosage used was
250 mg of octreotide subcutaneously every eight hours for 7 days.
This study had one of the lowest pancreatic ﬁstula rates ever
reported in the literature (9% for the placebo group and 11% for
the octreotide group). Surgeons performed either a pancreatico-
jejunostomy or a pancreatico-gastrostomy and the two groups
were comparable with respect to demographics, type of resection,
type of anastomosis and ﬁnal pathologic diagnosis. The overall
complication rate was 34% in the control group and 40% in the
octreotide group. Complications considered were death, re-oper-
ation, pancreatic ﬁstula, wound infection, delayed gastric
emptying, intra-abdominal abscess, cardiac arrhythmias, bile leak,
pancreatitis, cholangitis, hemobilia and ﬁnally, post-operative
hospital stay. In contrast to what was published at the time by 4
multicenter European studies, this trial reported no difference in
the complication rate between the two groups. Importantly, there
was also a subgroup analysis on the impact of octreotide based on
the pancreatic texture, i.e. soft, intermediate or hard as deﬁned by
the surgeon. There was no difference in complication rate be-
tween the subgroups. The authors also reported on the additional
economic burden by octreotide administration, estimated as an
additional 75$ per patient/per day. This is one of the very few
studies in the literature that has actually performed a cost-beneﬁt
analysis on the administration of the drug. They ﬁnally concluded
that the prophylactic perioperative use of octreotide is not
reducing the incidence of pancreatic ﬁstula, the overall compli-
cations, the mortality or the length of hospital stay and, that the
prophylactic use of octreotide should be eliminated at a consid-
erable cost savings.
Gouillat et al.4 assessed the effects of somatostatin -14 (S-14) on
pancreatic remnant exocrine secretion following pancreatic sur-
gery. In this RCT patients received a continuous infusion of either
S-14 or placebo, for 7 days. A total of 75 were enrolled in this study
e all underwent pancreaticoduodenectomy. The pancreatic anas-
tomosis technique was left at the discretion of each surgeon
however, the placement of a pancreatic duct tube to facilitate
collection of pancreatic juice was mandatory. Additionally, all pa-
tients had at least one drain placed in the vicinity of the pancreatic
anastomosis. The primary endpoint in this study was reduction in
pancreatic juice output. Secondary endpoints were amylase and
lipase output and concentration in both the pancreatic juice and
the drainage ﬂuid, incidence of clinically evident pancreatic ﬁstula,
total pancreatic stump-related complications and length of hos-
pital stay. The authors observed decreased incidence of both clin-
ical pancreatic ﬁstula occurrence (2/38 versus 8/37; p < 0.05) and
total stump-related complications (5/38 versus 12/37; p < 0.05) in
the study group. The duration of the hospital stay was also lower in
the S-14 group (18 versus 26 days; p < 0.01). However, in contrast,there was no difference in the primary endpoint of the study
(pancreatic juice output), even though the S-14 group had a lower
median output in the ﬁrst 7 days. The authors concluded that the
direct effect of S-14 on the exocrine secretion remains difﬁcult to
demonstrate.
In a more recent RCT by Kollmar et al.,5 the authors evaluated
the impact of octreotide on gastric emptying in patients under-
going pancreaticoduodenectomy. The primary endpoint was the
incidence of delayed gastric emptying but, a number of other
potential complications following pancreaticoduodenectomy
were assessed. Similar to the trial by Yeo et al.,3 the texture of the
pancreatic parenchyma was also assessed in this report. Gastric
emptying was evaluated by means of a gastric scintigraphy on
7th post-operative day. There were no differences between the
two groups in any of the primary or secondary endpoints. The
authors concluded that prophylactic administration of octreotide
in patients undergoing pancreaticoduodenectomy should be
avoided.
Lai et al.6 published a systematic review on measures to prevent
pancreatic ﬁstula following pancreaticoduodenectomy that pre-
ceded the most recent meta-analyses by Gurusamy et al.7 by three
years. This systematic review included the above RCTs except the
one reported by Kollmar et al.5 which was not published at the time
of data search. The review concludes that the use of octreotide to
prevent pancreatic ﬁstula remains controversial but there is strong
evidence that octreotide does not reduce mortality. The available
evidence qualiﬁes as level 1 and 2. The identiﬁed reasons for these
ﬁndings were poor pooling of data from RCTs and heterogeneity of
the available studies for endpoint measures, deﬁnition of outcome
measures, treatment regimes, pathologic ﬁndings, types of
pancreatic surgery and anastomotic technique.
Most recently, Gurusamy et al.7 published an updated meta-
analysis on this subject, including a total of 19 RCTs. In this re-
view, the initial attempt was to evaluate the beneﬁts from the
administration of octreotide in both distal and proximal pancre-
atic surgery and to subsequently perform a subgroup analysis. All
the RCTs presented here were part of this analysis and were of the
ones that received the highest score in the methodological quality
assessment. Out of 19 trials, 17 were classiﬁed as having a high
risk of bias with the reports by Gouillat et al.4 and Kollmar et al.5
being the two with the lowest risk. In total, 2245 patients were
analysed. There were no differences in the perioperative mortality
or in the number of patients with drug-related adverse effects
between the two groups. The overall number of patients with
post-operative complications was signiﬁcantly lower in the S/SA
group (RR 0.69; 95% CI 0.58e2.70; N ¼ 687), however there were
no differences in re-operation rate or hospital stay. The incidence
of pancreatic ﬁstula was lower in the S/SA group (RR 0.63; 95% CI
0.52e0.77; N ¼ 2161), although very few trials reported on the
proportion of these ﬁstulas that were clinically signiﬁcant. In the
subgroup analysis of those reporting on clinically signiﬁcant ﬁs-
tulas, there was no difference between the two groups. The au-
thors concluded that there is need for further adequately powered
trials having low risk of bias to address the question of whether
the use of prophylactic octreotide is beneﬁcial. Based on the
current available evidence S/SA are recommended for routine use
in patients undergoing pancreatic surgery. It should be outlined
however, that a subgroup analysis on different procedures (i.e.
distal pancreatectomy and. pancreaticoduodenectomy) was not
performed. This was because there were only two trials (the ones
by Gouillat et al.4 and Kollmar et al.5) that proved to have a low
risk of bias in the sensitivity analysis. Therefore, results from this
review need to be interpreted with caution when the issue is
pancreaticoduodenectomy rather than pancreatic surgery in
general.
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REVIEW7. Clinical bottom line
The administration of S/SA in pancreaticoduodenectomy re-
mains controversial, however it seems from the published litera-
ture that a clear beneﬁt is difﬁcult to show. There are very few
studies that have approached the issue and have a low risk of bias.
Furthermore, there are even fewer studies that have speciﬁcally
addressed certain subgroups of patients (soft versus hard texture,
malignant versus benign disease). Finally it seems that when
comparing data from different studies, distal and proximal
pancreatic surgery needs to be considered separately. There is a
need for further adequately powered, well designed RCTs
before deﬁnitive conclusions can be drawn. In the meantime, cur-
rent evidence supports that there is no decrease in the rate of
pancreatic ﬁstulas following octreotide administration in pan-
creaticoduodenectomies and therefore, octreotide should not be
administered routinely.
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